Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adverum Biotechnlgs (NQ: ADVM )

9.590 USD +0.190 (+2.02%)
Streaming Delayed Price Updated: 8:15 AM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Adverum Biotechnlgs

< Previous 1 2 3 4 5 Next >
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
From GlobeNewswire News Releases
Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
From GlobeNewswire News Releases
The Sonic Fund II, L.P. Files Preliminary Proxy Statement Relating to the Election of Highly Qualified Independent Directors at the 2021 Annual Meeting of Adverum Biotechnologies, Inc.
Issues Important Note to Shareholders to Ensure Shares Are Voteable at the 2021 Annual Meeting 
From PR Newswire
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
From GlobeNewswire News Releases
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
From GlobeNewswire News Releases
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results
From GlobeNewswire News Releases
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call 
From GlobeNewswire News Releases
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
From GlobeNewswire News Releases
Adverum Appoints Christopher J. DeRespino as Chief Business Officer
From GlobeNewswire News Releases
Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy
-- Long-term safety and sustained anti-VEGF protein expression out to 30 months following a single IVT injection of ADVM-022 in NHPs -- 
From GlobeNewswire News Releases
Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
From GlobeNewswire News Releases
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
From GlobeNewswire News Releases
Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
From GlobeNewswire News Releases
Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
From GlobeNewswire News Releases
Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science
From GlobeNewswire News Releases
Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter
From GlobeNewswire News Releases
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
From GlobeNewswire News Releases
Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)
From GlobeNewswire News Releases
Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.